OncoCyte Corporation

OncoCyte Corporation is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. OncoCyte Corporation is not a good value stock. OncoCyte Corporation is not a good growth stock. OncoCyte Corporation is a mediocre stock to choose.
Log in to see more information.
OncoCyte Corp. is a pharmaceutical company. It is focused on the discovery, development and commerci...
OCX Fundamental Data by TradingView

News

OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com
OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

Zolmax StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX - Get Free Report) in a report issued on Monday. The brokerage set a "sell" rating on the stock.\nSeparately, Needham Company...\n more…

OncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.com
OncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.com

Zolmax StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX - Free Report) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the stock.\nSeparately...\n more…

StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)
StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)

Ticker Report Research analysts at StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX - Get Free Report) in a note issued to investors on Tuesday. The firm set a "sell" rating on the stock...\n more…

OncoCyte (NASDAQ:OCX) and VolitionRx (NYSE:VNRX) Critical Contrast
OncoCyte (NASDAQ:OCX) and VolitionRx (NYSE:VNRX) Critical Contrast

Zolmax OncoCyte (NASDAQ:OCX - Get Free Report) and VolitionRx (NYSE:VNRX - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on...\n more…

StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)
StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)

Zolmax StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX - Free Report) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the stock.\nSeparately...\n more…

OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com
OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

Zolmax StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX - Free Report) in a research report released on Thursday. The firm issued a sell rating on the stock.\nSeparately, Needham &...\n more…